Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts

NORIAKI SAWADA, KUMIKO KONDOH and KAZUSHIGE MORI

Product Research Department, Kamakura Research Center, Chugai Pharmaceutical Co., Ltd.,
200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan

Received May 11, 2007; Accepted July 9, 2007

Abstract. We have evaluated the antitumor activity of XELOX (a combination therapy of capecitabine (Xeloda®) and oxaliplatin) in human colorectal and gastric cancer xenograft models. In human colorectal cancer model CXF280, antitumor activity of the combination at two-thirds of the maximum tolerated dose (MTD) was superior to that of each monotherapy at MTD. Furthermore, in human colorectal cancer model COL-05-JCK and human gastric cancer xenograft model GXF 97, the combination also showed at least additive antitumor activity. In addition, toxicity was not augmented with the combination therapy in these three models. As demonstrated using ELISA or immunohistochemistry, oxaliplatin in xenograft model tumors up-regulated the level of thymidine phosphorylase (dThdPase), a key enzyme for the metabolism of capecitabine to 5-fluorouracil. These results suggest that oxaliplatin might potentiate the antitumor activity of capecitabine by up-regulating the tumor level of dThdPase. Based on these results, clinical trials of XELOX against colorectal and gastric cancers are warranted.

Introduction

Capecitabine (Xeloda®) is one of the oral 5-fluoropyrimidine (5-FUra) derivatives and generates the active drug 5-FUra in tumors by a three-step cascade of enzymes located in the liver and tumor. The final step is the conversion of 5'-deoxyfluorouridine, an intermediated metabolite of capecitabine, to 5-FUra by thymidine phosphorylase (dThdPase), a key enzyme for the metabolism of capecitabine to 5-fluorouracil. These results suggest that oxaliplatin might potentiate the antitumor activity of capecitabine by up-regulating the tumor level of dThdPase. Based on these results, clinical trials of XELOX against colorectal and gastric cancers are warranted.

Materials and methods

Chemicals. Capecitabine was synthesized at Hoffmann-La Roche (Basel, Switzerland). Oxaliplatin was provided by Sanofi-Synthelabo (PA, USA).

Capecitabine was dissolved or suspended in 40 mM citrate buffer (pH 6.0) containing gum arabic and then administered orally once a day for 14 days followed by a week of rest. Oxaliplatin was injected on Day 1 and Day 22.

Animals. Four- or 5-week-old BALB/c nu/nu mice obtained from Charles River (Yokohama, Japan) and observed for at least 1 week were used in the experiments. All animal experiments were conducted in accordance with the guidelines for the Care and Use of Laboratory Animals in Nippon Roche Research Center (the former name of the affiliate of the authors).

Tumors. The human tumor lines used were the colorectal cancer line CXF280 and gastric cancer line GXF97 provided by Professor H.H. Fiebig (Freiberg University, Freiberg, Germany) and the colorectal cancer line COL-05-JCK from the Central Institute for Experimental Animals (Kanagawa, Japan).
Japan). All lines were maintained by continuous passage with pieces of tumor inoculated subcutaneously in the BALB/c nu/nu mice.

**Human cancer xenograft models.** A small piece of CXF280, COL-05-JCK, or GXF97 was inoculated subcutaneously into the right flank of a nude mouse. Administration of the drug started on the day when the mean volume of the tumors reached ~300-450 mm³. Tumor volume (V) was estimated using the equation $V = ab^2/2$, where $a$ and $b$ are tumor length and width, respectively. In the combination studies, mice bearing CXF280 or GXF97 were randomized into 6 mice per group and treated with the drugs. Mice bearing COL-05-JCK were randomized into 8 mice per group. To evaluate the efficacy of the drugs, tumor size and body weight were measured twice a week. In order to determine the levels of dThdPase in tumor, and for the immunohistochemical study, mice bearing CXF280 or COL-05-JCK were randomized into 4 mice per group and treated once with oxaliplatin. The tumors were excised 4 or 7 days after the drug administration to measure the dThdPase levels.

**Determination of tumor levels of dThdPase.** Tumor tissues were homogenized in 10 mM Tris-buffer (pH 7.4) containing 15 mM NaCl, 1.5 mM MgCl₂, and 50 μM potassium phosphate using a glass homogenizer. The homogenate was then centrifuged at 10,000 g for 20 min at 4°C, and the supernatants were stored at -80°C until use. The protein concentration of the supernatants was determined using a DC protein assay kit (Bio-Rad). The level of dThdPase was measured by ELISA with monoclonal antibodies specific to human dThdPase as previously described by Nishida et al. (12). One unit corresponds to the amount of dThdPase of a standard enzyme solution (extracts from human colon cancer xenograft HCT116) which phosphorolyzes 5'-DFUR to 5-FU at a rate of 1 μg 5-FUra per h. The ELISA results showed no cross-reactivity to mouse dThdPase.

**Immunohistochemistry for dThdPase.** Tumor tissues from human colorectal cancer xenograft model COL-05-JCK were fixed in a 10% neutral formalin solution, dehydrated with graded concentrations of ethanol, and embedded in paraffin. Deparaffinized 2-μm sections were washed in phosphate-buffer saline (PBS) for 5 min three times and steamed in a preheated steamer for 20 min. After removal and cool down for 20 min at room temperature, the sections were washed twice with distilled water. The sections were then treated with 0.3% H₂O₂ in absolute methanol to inactivate endogenous peroxidase and washed again with PBS for 5 min three times. The immunohistochemistry (IHC) method was as previously described (13). Slides were dehydrated and mounted with a non-aqueous permanent mounting medium. The anti-dThdPase IgG used was purified from rabbit antiserum by affinity column with recombinant dThdPase. As the second antibody for IHC, we used biotinylated anti-rabbit IgG antibody. The IHC-staining images of the tumor tissues were captured with a digital camera and the ratio of the area of dThdPase-positive cells to the area of tumor cells in the tumor tissues was calculated using Win Roof (Mitani Corp., Inc., Fukui, Japan).

**Results**

**Combination therapy.** The antitumor activity of capecitabine in combination with oxaliplatin was evaluated in human colon cancer xenograft model CXF280. The combination therapy of capecitabine at 2/3 MTD with oxaliplatin at 2/3 MTD showed significantly higher antitumor activity than each monotherapy at MTD (Fig. 1). In addition, no augmentation of toxicity, as shown by body weight loss, was observed in the combination treatment.

The combination of these drugs was also evaluated in human colon cancer xenograft model COL-05-JCK. Oxaliplatin alone showed no significant antitumor activity and no significant delay of tumor growth in this model. However, the combination therapy showed significant tumor growth delay as compared with capecitabine alone (Fig. 2), although the tumor growth inhibition estimated from tumor volume was not significant.

Furthermore, the XELOX combination showed at least additive effect in human gastric cancer xenograft model GXF97 (Fig. 3). Two of the 6 mice in the combination group had no palpable tumor one week after 2 cycles of the treatment.

**dThdPase up-regulation.** We measured the level of dThdPase in tumor tissues of the CXF280 and COL-05-JCK models treated with oxaliplatin using ELISA. Levels of dThdPase in tumor were significantly increased 7 days after single administration of oxaliplatin in the CXF280 model (Table I).

![Graph](image-url)
On the other hand, in the COL-05-JCK model, no significant increase in dThdPase activity was observed in tumor tissue 4 or 7 days after treatment with oxaliplatin. To investigate the tumor cell expression of dThdPase in the COL-05-JCK model, we conducted an immunohistochemistry (IHC) examination. The ratio of the area of dThdPase-positive cells to the area of tumor cells in the tumor tissues after the treatment with oxaliplatin tended to be higher than that of the vehicle control (Table II, Fig. 4), although it was not significantly different.

**Discussion**

We have previously reported that some antitumor drugs, such as taxanes and cyclophosphamide, and X-ray irradiation up-regulated dThdPase in tumor tissues. We have also reported that capecitabine in combination with these dThdPase up-regulators showed a synergistic antitumor activity in human cancer xenograft models (6-8). In the present study, the combination of capecitabine and oxaliplatin showed supra-additive antitumor activity in human gastrointestinal cancer xenograft models. The combination therapy of capecitabine at 2/3 MTD with oxaliplatin at 2/3 MTD showed significantly higher antitumor activity than each monotherapy at MTD.

Oxaliplatin was intravenously administered in human colon cancer xenograft model CXF280. Tumor tissues were excised to measure dThdPase levels at 7 days after administration of oxaliplatin.

On the other hand, in the COL-05-JCK model, no significant increase in dThdPase activity was observed in tumor tissue 4 or 7 days after treatment with oxaliplatin. To investigate the tumor cell expression of dThdPase in the COL-05-JCK model, we conducted an immunohistochemistry (IHC) examination. The ratio of the area of dThdPase-positive cells to the area of tumor cells in the tumor tissues after the treatment with oxaliplatin tended to be higher than that of the vehicle control (Table II, Fig. 4), although it was not significantly different.

**Discussion**

We have previously reported that some antitumor drugs, such as taxanes and cyclophosphamide, and X-ray irradiation up-regulated dThdPase in tumor tissues. We have also reported that capecitabine in combination with these dThdPase up-regulators showed a synergistic antitumor activity in human cancer xenograft models (6-8). In the present study, the combination of capecitabine and oxaliplatin showed supra-additive antitumor activity in human gastrointestinal cancer xenograft models. The combination therapy of capecitabine at 2/3 MTD with oxaliplatin at 2/3 MTD showed significantly higher antitumor activity than each monotherapy at MTD.
oxaliplatin on day 7 or 15 of the treatment. The antitumor activity of capecitabine in this model as well. To investigate the possibility that capcitabine might enhance the efficacy of oxaliplatin, we examined another administration schedule of capcitabine treatment for 14 days, followed by oxaliplatin on day 7 or 15 of the treatment. The antitumor activity of oxaliplatin in this schedule was not augmented by the pretreatment of capcitabine (data not shown).

In the present pre-clinical study, the combination therapy of capcitabine with oxaliplatin showed superior antitumor activity at the lower dose of 2/3 MTD. It is suggested that the up-regulation of dThdPase by oxaliplatin in tumor tissue would allow a dose reduction of capcitabine with potentiation of antitumor activity. A recent Phase II study of the combination therapy of capcitabine and oxaliplatin for metastatic colorectal cancer showed a favorable safety profile of response rates, time to progression, and overall survival (11). Further clinical study using the combination of capcitabine and oxaliplatin is warranted for colorectal and gastric cancers.

References


**Table II. Up-regulation of dThdPase by oxaliplatin.**

<table>
<thead>
<tr>
<th>Sample</th>
<th>dThdPase level (unit/mg protein) (fold)</th>
<th>Ratio of dThdPase-positive cells (%) (fold)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vehicle</td>
<td>9.7±1.5 (-)</td>
<td>2.9±3.9 (-)</td>
</tr>
<tr>
<td>Oxaliplatin 10 mg/kg</td>
<td>11.5±3.0 (1.2)</td>
<td>11.7±5.5 (4.0)</td>
</tr>
<tr>
<td>Day 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vehicle</td>
<td>8.2±0.6 (-)</td>
<td>4.1±1.7 (-)</td>
</tr>
<tr>
<td>Oxaliplatin 10 mg/kg</td>
<td>11.5±4.1 (1.4)</td>
<td>11.2±9.4 (2.7)</td>
</tr>
</tbody>
</table>